| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.9M | — | +453.4% |
| SG&A Expense | $3.8M | — | +262.8% |
| Operating Income | -$5.6M | — | -274.1% |
| Net Income | -$6.2M | — | -312.9% |
| EPS (Basic) | -$2.23 | — | +11.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.2M | -42.9% | +978.5% |
| Inventory | $750K | — | +145.1% |
| Current Assets | $8.7M | -33.5% | +586.1% |
| Total Assets | $38.2M | +20.9% | +911.8% |
| Current Liabilities | $2.6M | +304.8% | +252.9% |
| Total Liabilities | $19.7M | +164.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.0M | — | -463.7% |
| Capital Expenditures | $7K | — | — |
| Investing Cash Flow | -$7K | — | +98.7% |
| Financing Cash Flow | -$44K | — | -153.7% |
| Free Cash Flow | -$5.0M | — | -464.5% |
| +2554.1% |
| Stockholders' Equity | $11.1M | -34.1% | +264.4% |